Crossmark

Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838–40. Clinical Utility of Trial-estimated Prognostic Models

Crossref DOI link: https://doi.org/10.1016/j.eururo.2017.04.031

Published Print: 2017-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Seyednasrollah, Fatemeh https://orcid.org/0000-0002-1530-1389
Mahmoudian, Mehrad

Rautakorpi, Liisa

Hirvonen, Outi

Laitinen, Tarja

Jyrkkiö, Sirkku

Elo, Laura L.
License Information

Text and Data Mining valid from 2017-09-01
More Information

This article is maintained by: Elsevier

Article Title: Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838–40. Clinical Utility of Trial-estimated Prognostic Models

Journal Title: European Urology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eururo.2017.04.031

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.eururo.2017.01.043

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.eururo.2017.04.030

Content Type: simple-article

Copyright: © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Document is current

Any future updates will be listed below